**INTRODUCTION:** Chemotherapy has been shown to adversely affect post-operative outcomes in a variety of surgical fields, leading to delayed wound healing and increased susceptibility to infections. We aim to analyze the impact of chemotherapy timing on wound infections after immediate breast reconstruction (IBR).

**METHODS:** A single-center, retrospective chart review of patients undergoing IBR between 2010 and 2015 was performed. Patients were divided into four groups: those with neoadjuvant chemotherapy only, adjuvant chemotherapy only, both adjuvant and neoadjuvant, and those with no chemotherapy. Subgroup comparisons were made. Outcomes of interest included surgical site infection and timing of post-operative wound infection.

**RESULTS:** A total of 949 reconstructions were performed over the study period. Subgroup breakdown was as follows: 56 (5.9%) neoadjuvant only, 173 (18.2%) adjuvant only, 18 (1.9%) both, and 702 (74.0%) none. Overall infection rates were 10.7%, 10.4%, 22.2%, and 6.1% in the four groups, respectively (p=0.015). On multivariate analysis, no significant differences were observed when comparing presence or absence of chemotherapy in the overall reconstruction cohort or when subgrouped by reconstruction modality -- autologous or alloplastic. There were no significant differences in time from neoadjuvant chemotherapy to surgery date noted between patients who developed a post-operative surgical site infection and those who did not (4.40 ± 1.58 vs 4.72 ± 1.39 weeks; p=0.517).

**CONCLUSION:** In our study, chemotherapy timing did not increase the odds of surgical site infections in patients undergoing immediate breast reconstruction.
